Arvanil-induced inhibition of spasticity and persistent pain: evidence for therapeutic sites of action different from the vanilloid VR1 receptor and cannabinoid CB 1 /CB 2 receptors

Author： Brooks J.W.   Pryce G.   Bisogno T.   Jaggar S.I.   Hankey D.J.R.   Brown P.   Bridges D.   Ledent C.   Bifulco M.   Rice A.S.C.   Di Marzo V.   Baker D.  

Publisher： Elsevier

ISSN： 0014-2999

Source： European Journal of Pharmacology, Vol.439, Iss.1, 2002-03, pp. : 83-92

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Relative involvement of cannabinoid CB 1 and CB 2 receptors in the 9 -tetrahydrocannabinol-induced inhibition of natural killer activity

By Massi P.   Fuzio D.   Vigano D.   Sacerdote P.   Parolaro D.  

European Journal of Pharmacology, Vol. 387, Iss. 3, 2000-01 ,pp. : 343-347

Elsevier

Access to resources Recommend Favorite

CB1 Cannabinoid Receptor Ligands

By  

Mini Reviews in Medicinal Chemistry, Vol. 5, Iss. 7, 2005-07 ,pp. : 631-640

Bentham Science Publishers

Access to resources Recommend Favorite

The Role of the Cannabinoid CB2 Receptor in Pain Transmission and Therapeutic Potential of Small Molecule CB2 Receptor Agonists

By  

Current Medicinal Chemistry, Vol. 14, Iss. 8, 2007-04 ,pp. : 917-936

Bentham Science Publishers

Access to resources Recommend Favorite

Recent Development of CB2 Selective and Peripheral CB1/CB2 Cannabinoid Receptor Ligands

By  

Current Medicinal Chemistry, Vol. 21, Iss. 2, 2014-01 ,pp. : 187-203

Bentham Science Publishers

Access to resources Recommend Favorite

Cannabinoid CB1 and CB2 Receptor Ligand Specificity and the Development of CB2-Selective Agonists

By  

Current Medicinal Chemistry, Vol. 15, Iss. 14, 2008-06 ,pp. : 1428-1443

Bentham Science Publishers

Access to resources Recommend Favorite